ALTEOGEN Inc. Overview
Pro stress-test →Alteogen is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. The company was founded in 2008 and listed on KOSDAQ. Its portfolio targets high-value therapeutic areas including cancer, endocrinology, and rare blood disorders.
Strategic Profile
Pro stress-test →Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. The company also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. Recent partnerships with GSK and other major pharmaceutical companies validate its technology platforms and expand commercialization opportunities.
Competitive Landscape
Pro stress-test →Alteogen competes in the specialized biotech sector focused on biobetters, ADCs, and biosimilars. Direct competitors include other Korean biotechs (Celltrion, Genexine, ABL Bio) with biosimilar/biotherapeutic expertise, plus global biotech firms developing ADC and long-acting therapeutic platforms. Alteogen's differentiation lies in its integrated proprietary platforms and strategic partnerships with major pharma, though it faces competition from well-capitalized global players.
Industry Context
ALTEOGEN Inc. operates in Biopharmaceuticals - Specialized (Biobetters, Antibody-Drug Conjugates, Biosimilars).
Key facts
Founded: 2008 · Headquarters: Daejeon, South Korea · Employees: 154 · Revenue: N/A · Market cap: N/A